- call +1-201-465-4211
- email sales@mrinsights.biz
HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms. It can be mainly distinguished on how the infection was acquired.
Scope of the Report:
This report focuses on the Hospital-Acquired Pneumonia (HAP) Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
One trend in the market is combination therapy for the treatment of HAP. Monotherapy is the common treatment given for nosocomial pneumonia. However, combination therapy has sometimes been found to be more appropriate and desirable treatment.
One driver in the market is unmet demand due to lack of available treatment for MDR microorganisms. Lack of proper treatment options available for the treatment of HAP because of MDR microorganisms is a major challenge for the healthcare providers. MDR microorganisms are those microorganisms that have developed antimicrobial drugs resistance. The resistance among various microorganisms to various antimicrobial drugs has emerged as a serious threat to public health across the globe.
The worldwide market for Hospital-Acquired Pneumonia (HAP) Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Pfizer
Merck
Mylan
Novartis
Teva Pharmaceutical Industries
AstraZeneca
Shinogi
Sun Pharmaceutical Industries
The Medicines Company
Theravance Biopharma
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Antibacterial
Antiviral
Antifungal
Market Segment by Applications, can be divided into
Hospitals
Clinics
Others
There are 15 Chapters to deeply display the global Hospital-Acquired Pneumonia (HAP) Drugs market.
Chapter 1, to describe Hospital-Acquired Pneumonia (HAP) Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, with sales, revenue, and price of Hospital-Acquired Pneumonia (HAP) Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Hospital-Acquired Pneumonia (HAP) Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Hospital-Acquired Pneumonia (HAP) Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Hospital-Acquired Pneumonia (HAP) Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Hospital-Acquired Pneumonia (HAP) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Antibacterial
1.2.2 Antiviral
1.2.3 Antifungal
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Hospital-Acquired Pneumonia (HAP) Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Merck
2.2.1 Business Overview
2.2.2 Hospital-Acquired Pneumonia (HAP) Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Mylan
2.3.1 Business Overview
2.3.2 Hospital-Acquired Pneumonia (HAP) Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novartis
2.4.1 Business Overview
2.4.2 Hospital-Acquired Pneumonia (HAP) Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Teva Pharmaceutical Industries
2.5.1 Business Overview
2.5.2 Hospital-Acquired Pneumonia (HAP) Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 AstraZeneca
2.6.1 Business Overview
2.6.2 Hospital-Acquired Pneumonia (HAP) Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Shinogi
2.7.1 Business Overview
2.7.2 Hospital-Acquired Pneumonia (HAP) Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Sun Pharmaceutical Industries
2.8.1 Business Overview
2.8.2 Hospital-Acquired Pneumonia (HAP) Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 The Medicines Company
2.9.1 Business Overview
2.9.2 Hospital-Acquired Pneumonia (HAP) Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Theravance Biopharma
2.10.1 Business Overview
2.10.2 Hospital-Acquired Pneumonia (HAP) Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Hospital-Acquired Pneumonia (HAP) Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Hospital-Acquired Pneumonia (HAP) Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Analysis by Regions
4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
4.5 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
5 North America Hospital-Acquired Pneumonia (HAP) Drugs by Countries
5.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
6 Europe Hospital-Acquired Pneumonia (HAP) Drugs by Countries
6.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
6.3 UK Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
6.4 France Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs by Countries
7.1 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
7.5 India Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
8 South America Hospital-Acquired Pneumonia (HAP) Drugs by Countries
8.1 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Hospital-Acquired Pneumonia (HAP) Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Hospital-Acquired Pneumonia (HAP) Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs by Countries
9.1 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2013-2018)
10 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Segment by Type
10.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue and Market Share by Type (2013-2018)
10.2 Antibacterial Sales Growth and Price
10.2.1 Global Antibacterial Sales Growth (2013-2018)
10.2.2 Global Antibacterial Price (2013-2018)
10.3 Antiviral Sales Growth and Price
10.3.1 Global Antiviral Sales Growth (2013-2018)
10.3.2 Global Antiviral Price (2013-2018)
10.4 Antifungal Sales Growth and Price
10.4.1 Global Antifungal Sales Growth (2013-2018)
10.4.2 Global Antifungal Price (2013-2018)
11 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Segment by Application
11.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Clinics Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast (2018-2023)
12.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast (2018-2023)
12.2.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast (2018-2023)
12.2.4 South America Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast (2018-2023)
12.3 Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share Forecast by Type (2018-2023)
12.4 Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Hospital-Acquired Pneumonia (HAP) Drugs Picture
Table Product Specifications of Hospital-Acquired Pneumonia (HAP) Drugs
Figure Global Sales Market Share of Hospital-
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
